Avalon GloboCare Appoints Prominent Life Science M&A Attorney Steven Sanders to the Board of Directors
FREEHOLD, N.J., July 31, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company has appointed Steven Sanders, Esq. to the Board of Directors.
Mr. Sanders brings over four decades of experience within the specialized areas of corporate, securities and international law. He has experience representing life science companies including both public and private companies. He has also represented both underwriters and issuers on a variety of public and private financings. He has held senior positions at leading U.S. and international law firms, and founded the Ortoli Rosenstadt LLP law firm, headquartered in New York City, which has represented both domestic and international clients across many industries including life sciences, in areas such as mergers, acquisitions and a variety of other transactions. Steven is a member of the American Bar Association and the New York State Bar Association and the Bar of the City of New York, where he previously served on the European Affairs Committee. In addition, Mr. Sanders sits on the boards of other companies including Helijet International, Inc. and Electrameccanica Vehicles, as well as non-profits such as the American Academy of Dramatic Arts, and the Bay Street Theater. He previously served on the board of the Roundabout Theatre Company, the largest non-profit theater in America and Town Hall. He also was the former Honorary Consul from the Republic of Moldova.
Dr. David Jin, President and CEO of Avalon GloboCare, stated, “We are pleased to welcome Steven Sanders to our Board of Directors. He brings an impressive corporate and international law background, as well as extensive capital markets and M&A experience. He also brings a wealth of knowledge in the life sciences industry. Steve will be an invaluable asset as we pursue strategic partnerships and acquisitions within the cell-therapy industry.”
Steven Sanders commented, “I am delighted to join Avalon’s Board of Directors. The field of cell therapy is undergoing rapid transformation, as evidenced by recent advancements in immuno-oncology and regenerative medicine. Avalon’s exosome technologies and cell-based therapies, as well as its network of leading research institutions in the U.S. and China, place it at the forefront of this emerging market. I look forward to helping Avalon advance its mission of bringing cutting edge therapies to market and saving lives.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its U.S. subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon will further establish our leading roles in the fields of CAR-T therapy, liquid biopsy, precision medicine and regenerative medicine.
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
Crescendo Communications, LLC
Tel: (212) 671-1020
Released July 31, 2018